Tiziana Life Sciences Ltd Com Financials
This page shows Tiziana Life Sciences Ltd Com (TLSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiziana’s latest statements show a development-stage financing cycle: operating cash consumption is funded externally while equity capital has nearly disappeared.
The free-cash-flow deterioration from-$1.5M in FY2024 to-$12.9M in FY2025 indicates a worsening operating burden, not simply a temporary investment spike. With FY2025 capital spending at only$21K , the cash shortfall reflects ongoing operating economics rather than a heavier reinvestment cycle.
Equity fell from
FY2025’s net loss of
Financial Health Signals
Tiziana Life Sciences Ltd Com does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Tiziana Life Sciences Ltd Com passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Tiziana Life Sciences Ltd Com reported a net loss of $18.4M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Tiziana Life Sciences Ltd Com reported -$18.4M in net income in fiscal year 2025. This represents a decrease of 55.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Tiziana Life Sciences Ltd Com recorded an outflow of $12.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 732.9% from the prior year.
Tiziana Life Sciences Ltd Com held $4.0M in cash against $234K in long-term debt as of fiscal year 2025, with $11.2M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Tiziana Life Sciences Ltd Com's ROE was -35444.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 35142.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Tiziana Life Sciences Ltd Com invested $21K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
TLSA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Interest Expense | $18K+200.0% | $6K-40.0% | $10K+42.9% | $7K-46.2% | $13K-23.5% | $17K-45.2% | $31K+358.3% | -$12K0.0% | -$12K0.0% | -$12K |
| Income Tax | -$4.9M0.0% | -$4.9M-1187.5% | $449K | N/A | -$3.2M-46.8% | -$2.2M0.0% | -$2.2M-13.5% | -$1.9M-1.7% | -$1.9M-1480.2% | -$121K |
| Net Income | -$18.4M-55.4% | -$11.9M+32.9% | -$17.7M-14.9% | -$15.4M+34.2% | -$23.4M+10.4% | -$26.1M-180.3% | -$9.3M-17.5% | -$7.9M+7.7% | -$8.6M+12.0% | -$9.8M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
TLSA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.5M+1.9% | $11.3M-7.4% | $12.2M-54.0% | $26.5M-45.8% | $48.8M-30.9% | $70.7M+2871.2% | $2.4M-65.6% | $6.9M+180.0% | $2.5M | N/A |
| Current Assets | $8.6M+13.9% | $7.5M+2.3% | $7.3M-69.8% | $24.3M-50.1% | $48.7M-30.6% | $70.2M+4562.9% | $1.5M-78.2% | $6.9M+182.4% | $2.4M | N/A |
| Cash & Equivalents | $4.0M+7.7% | $3.7M+214.8% | $1.2M-93.5% | $18.1M-57.0% | $42.2M-35.9% | $65.8M+32812.0% | $200K-96.2% | $5.3M+8187.5% | $64K-98.9% | $5.8M |
| Total Liabilities | $11.4M+55.7% | $7.3M+10.5% | $6.6M-3.7% | $6.9M-8.5% | $7.5M-8.8% | $8.3M+112.3% | -$67.3M+2.3% | -$68.8M-1549.7% | $4.7M | N/A |
| Current Liabilities | $11.2M+52.5% | $7.3M+12.4% | $6.5M-1.9% | $6.7M-11.7% | $7.5M-5.4% | $8.0M+8.6% | $7.4M+14.8% | $6.4M+34.8% | $4.7M | N/A |
| Long-Term Debt | $234K | N/A | $109K-55.1% | $243K | N/A | $290K-46.4% | $541K-35.5% | $839K+189.3% | $290K+4.3% | $278K |
| Total Equity | $52K-98.7% | $3.9M-28.9% | $5.5M-71.7% | $19.6M-52.6% | $41.3M-33.8% | $62.4M-10.4% | $69.6M-8.1% | $75.8M+3426.1% | -$2.3M-155.7% | $4.1M |
| Retained Earnings | -$163.1M-12.6% | -$144.8M-8.3% | -$133.7M-15.0% | -$116.3M-7.6% | -$108.1M-27.7% | -$84.6M-41.0% | -$60.0M-18.4% | -$50.7M-19.0% | -$42.6M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TLSA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.8M-741.9% | -$1.5M+90.3% | -$15.7M+20.0% | -$19.6M+9.9% | -$21.8M-92.0% | -$11.3M-66.8% | -$6.8M-47.7% | -$4.6M+38.9% | -$7.5M | N/A |
| Capital Expenditures | $21K+10.5% | $19K | N/A | N/A | $22K+633.3% | $3K-25.0% | $4K | N/A | $1K-97.9% | $48K |
| Free Cash Flow | -$12.9M-732.9% | -$1.5M | N/A | N/A | -$21.8M-92.1% | -$11.3M-66.7% | -$6.8M | N/A | -$7.5M | N/A |
| Investing Cash Flow | $3.0M+4385.9% | -$71K+94.3% | -$1.3M+68.6% | -$4.0M-3173.8% | $130K+205.7% | -$123K-2975.0% | -$4K | N/A | -$1K+99.7% | -$342K |
| Financing Cash Flow | $10.0M+122.1% | $4.5M+11162.5% | $40K+172.7% | -$55K-139.1% | -$23K-100.0% | $75.3M+4384.9% | $1.7M-83.4% | $10.1M+554.4% | $1.5M-2.1% | $1.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TLSA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -35444.2%-35142.8pp | -301.4%+18.2pp | -319.6%-240.9pp | -78.7%-21.9pp | -56.7%-14.8pp | -41.9%-28.5pp | -13.4%-2.9pp | -10.5% | N/A | -239.0% |
| Return on Assets | -160.3%-55.2pp | -105.1%+40.1pp | -145.2%-87.0pp | -58.1%-10.2pp | -48.0%-11.0pp | -37.0%+355.1pp | -392.1%-277.4pp | -114.7%+233.1pp | -347.8% | N/A |
| Current Ratio | 0.76-0.3x | 1.02-0.1x | 1.12-2.5x | 3.64-2.8x | 6.45-2.3x | 8.79+8.6x | 0.20-0.9x | 1.08+0.6x | 0.52 | N/A |
| Debt-to-Equity | 4.50+2.6x | 1.87+1.8x | 0.020.0x | 0.01-0.2x | 0.18+0.2x | 0.000.0x | 0.010.0x | 0.01 | N/A | 0.07 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.76), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Tiziana Life Sciences Ltd Com Ranks
Frequently Asked Questions
Is Tiziana Life Sciences Ltd Com profitable?
No, Tiziana Life Sciences Ltd Com (TLSA) reported a net income of -$18.4M in fiscal year 2025.
How much debt does Tiziana Life Sciences Ltd Com have?
As of fiscal year 2025, Tiziana Life Sciences Ltd Com (TLSA) had $4.0M in cash and equivalents against $234K in long-term debt.
What is Tiziana Life Sciences Ltd Com's return on equity (ROE)?
Tiziana Life Sciences Ltd Com (TLSA) has a return on equity of -35444.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tiziana Life Sciences Ltd Com's free cash flow?
Tiziana Life Sciences Ltd Com (TLSA) recorded an outflow of $12.9M in free cash flow during fiscal year 2025. This represents a -732.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tiziana Life Sciences Ltd Com's operating cash flow?
Tiziana Life Sciences Ltd Com (TLSA) recorded an outflow of $12.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tiziana Life Sciences Ltd Com's total assets?
Tiziana Life Sciences Ltd Com (TLSA) had $11.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tiziana Life Sciences Ltd Com's capital expenditures?
Tiziana Life Sciences Ltd Com (TLSA) invested $21K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Tiziana Life Sciences Ltd Com's current ratio?
Tiziana Life Sciences Ltd Com (TLSA) had a current ratio of 0.76 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Tiziana Life Sciences Ltd Com's debt-to-equity ratio?
Tiziana Life Sciences Ltd Com (TLSA) had a debt-to-equity ratio of 4.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tiziana Life Sciences Ltd Com's return on assets (ROA)?
Tiziana Life Sciences Ltd Com (TLSA) had a return on assets of -160.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Tiziana Life Sciences Ltd Com's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tiziana Life Sciences Ltd Com (TLSA) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.8M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Tiziana Life Sciences Ltd Com's Piotroski F-Score?
Tiziana Life Sciences Ltd Com (TLSA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tiziana Life Sciences Ltd Com's earnings high quality?
Tiziana Life Sciences Ltd Com (TLSA) reported a net loss of $18.4M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.